Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13514
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBurrows, Graham Den
dc.contributor.authorKremer, C Men
dc.date.accessioned2015-05-16T03:23:07Z
dc.date.available2015-05-16T03:23:07Z
dc.date.issued1997-04-01en
dc.identifier.citationJournal of Clinical Psychopharmacology; 17 Suppl 1(): 34S-39Sen
dc.identifier.govdoc9090576en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/13514en
dc.description.abstractMirtazapine is a noradrenergic and specific serotonergic antidepressant, characterized by a unique pharmacologic profile, favorable pharmacokinetics, and proven efficacy and safety. Mirtazapine has demonstrated clinical efficacy in the treatment of moderately and severely depressed patients. In addition, mirtazapine was found to be equally effective as clomipramine in the treatment of severely depressed, hospitalized patients. The overall improvement with mirtazapine is seen after 1 week of treatment and is sustained throughout the treatment period. It is paralleled by an improvement in depressed mood, the core symptom of depressive illness. Because of its unique pharmacologic profile, mirtazapine is virtually devoid of anticholinergic, adrenolytic, and serotonin-related side effects. The most frequently reported adverse events were transient sedation and weight gain.en
dc.language.isoenen
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAmitriptyline.therapeutic useen
dc.subject.otherAntidepressive Agents, Tricyclic.adverse effects.therapeutic useen
dc.subject.otherClinical Trials as Topicen
dc.subject.otherClomipramine.therapeutic useen
dc.subject.otherDepressive Disorder.drug therapyen
dc.subject.otherEating Disorders.chemically induceden
dc.subject.otherHumansen
dc.subject.otherMianserin.adverse effects.analogs & derivatives.therapeutic useen
dc.subject.otherSleep Stagesen
dc.subject.otherWeight Gainen
dc.titleMirtazapine: clinical advantages in the treatment of depression.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of clinical psychopharmacologyen
dc.identifier.affiliationDepartment of Psychiatry, University of Melbourne, Austin, Australiaen
dc.description.pages34S-39Sen
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/9090576en
dc.type.austinJournal Articleen
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

16
checked on Dec 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.